Preoperative Risk Assessment of Pancreatic Fistula Impact on Adjuvant Chemotherapy Delivery After Pancreatoduodenectomy. in Annals of surgical oncology / Ann Surg Oncol. 2026 Sep;33(9):8394-8404. doi: 10.1245/s10434-026-19447-x. Epub 2026 Apr 24.
2026
AOU Alessandria
AOU Alessandria
Tipo pubblicazione
Multicenter Study
Autori/Collaboratori (42)Vedi tutti...
Tzedakis S
General and Oncologic Surgery, Morgagni-Pierantoni Hospital, Forlì, Italy.
Pessaux P
Department of Hepato-Bilio-Pancreatic Surgery and Organ Transplantation, University Hospital San Martino, Genoa, Italy.
Ielpo B
Chirurgia Epatobiliopancreatica, AOU Careggi, Florence, Italy.
et alii...
General and Oncologic Surgery, Morgagni-Pierantoni Hospital, Forlì, Italy.
Pessaux P
Department of Hepato-Bilio-Pancreatic Surgery and Organ Transplantation, University Hospital San Martino, Genoa, Italy.
Ielpo B
Chirurgia Epatobiliopancreatica, AOU Careggi, Florence, Italy.
et alii...
Abstract
BACKGROUND: Up to 40% of patients undergoing pancreatoduodenectomy (PD) for resectable pancreatic ductal adenocarcinoma do not receive adjuvant chemotherapy (aCT). This study aimed to evaluate the impact of postoperative pancreatic fistula (POPF) on aCT delivery and timing and to explore how preoperative variables influence these outcomes according to the occurrence of a POPF. METHODS: This multicenter retrospective study included patients from 25 pancreatic centers. Propensity score matching was performed based on anatomical, biological, and conditional variables. Multivariable regression analyses were used to identify independent predictors of aCT omission and delay. RESULTS: Among 1590 patients, 267 (16.8%) developed a POPF. Overall, aCT was administrated in 1,146 patients (72.1%) with a median time to first dose delivery of 56 days (26). After matching, POPF was associated with a significantly lower likelihood of aCT delivery (p < 0.001) and a significant delay in its initiation (p < 0.001). Independent predictors of aCT omission were age ? 70 (odds ratio [OR] 2.480, 95% confidence interval [CI] 1.439-4.274; p < 0.001), chronic renal failure (OR 4.554, 95% CI 1.320-15.708; p = 0.016), and chronic obstructive pulmonary disease (OR 2.775, 95% CI 1.021-7.546; p = 0.045) when POPF occurred. In the absence of POPF, apart from age ? 70, venous contact (OR 1.574, 95% CI 1.114-2.224; p = 0.010) and tumor size > 20 mm (OR 0.713, 95% CI 0.523-0.972; p = 0.032) were predictors of aCT delivery. CONCLUSIONS: Postoperative pancreatic fistula is a key driver of aCT delivery after pancreatoduodenectomy. Its interaction with patient frailty highlights the need for preoperative risk assessment to better select candidates for upfront surgery in resectable pancreatic ductal adenocarcinoma.
Accesso banca dati bibliografica
Accedi alla scheda bibliografica del documento in PUBMED
Se sei accreditato in BVS-P effettua prima l'accesso per utilizzare i nostri servizi.
PMID : 42029857
DOI : 10.1245/s10434-026-19447-x
Keywords
Pancreatic Fistula/etiology; Pancreaticoduodenectomy/adverse effects; Humans; Female; Male; Retrospective Studies; Pancreatic Neoplasms/pathology/surgery/drug therapy; Chemotherapy, Adjuvant/adverse effects; Aged; Carcinoma, Pancreatic Ductal/surgery/drug therapy/pathology; Follow-Up Studies; Risk Assessment; Prognosis; Middle Aged; Postoperative Complications/etiology; Risk Factors; Survival Rate; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Preoperative Care; Adjuvant chemotherapy; Conditional status; Pancreatic cancer; Pancreatic fistula; Pancreatoduodenectomy;